ContraFect's Series B Round

ContraFect raised a round of funding on October 21, 2010. Investors include Maxim Group.

ContraFect is a biotechnology company committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms-including gram-positive ba…

Articles about ContraFect's Series B Round: